Immunotherapy and radiation before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests giving immunotherapy combined with a precise, high-dose radiation boost before surgery for HER2-negative breast cancer. The goal is to see if this approach can improve outcomes, especially for cancers that are more advanced or have spread to a few other spots in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and diagnosed with invasive breast cancer.
- Your cancer must be HER2-negative and either hormone-receptor-negative (ER<1%, PR<1%) or a luminal type.
- Your breast cancer must be at least stage II with lymph node involvement, or stage IV with a limited number of metastases (up to 3 in one organ or 2 total in two organs) that can be treated with surgery or radiation.
- You cannot have had chemotherapy for this breast cancer before (except possibly one cycle of AC).
- You must be able to have a breast MRI and not have a metal implant or device that prevents it.
- You must not have an active autoimmune disease requiring immune-suppressing medication or a history of certain lung infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests adding radiation therapy to chemotherapy before surgery for people with locally advanced breast cancer that did not shrink enough with chemo alone. It may help improve outcomes for those with luminal (HER2-negative) or triple-negative types.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.